` 002399 (Shenzhen Hepalink Pharmaceutical Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

002399
vs
Shanghai Composite

Over the past 12 months, has outperformed Shanghai Composite, delivering a return of 21% compared to the Shanghai Composite's 7% growth.

Stocks Performance
002399 vs Shanghai Composite

Loading

Performance Gap
002399 vs Shanghai Composite

Loading
002399
Shanghai Composite
Difference

Performance By Year
002399 vs Shanghai Composite

Loading
002399
Shanghai Composite
Add Stock

Competitors Performance
Shenzhen Hepalink Pharmaceutical Group Co Ltd vs Peers

Shanghai Composite
002399
LLY
JNJ
NOVO B
ROG
Add Stock

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
16.3B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.

Intrinsic Value
11.99 CNY
Undervaluation 7%
Intrinsic Value
Price
S
Back to Top